Medicare to Offer $50 Monthly Cap on GLP-1 Weight Loss Medications Starting July 2026

Starting July 2026, Medicare Part D beneficiaries will gain access to GLP-1 receptor agonist medications for weight loss at a capped monthly cost of $50. This initiative aims to improve health outcomes and address obesity, a growing public health concern. Currently, medications like Wegovy and Zepbound are not covered by Medicare for weight loss, but this latest program will provide a significant financial benefit for eligible individuals.

Who Qualifies for the $50 Monthly Cap?

To be eligible for the reduced cost, beneficiaries must meet specific criteria:

• The medication must be prescribed to reduce excess body weight and maintain weight reduction in combination with ongoing lifestyle modifications, including structured nutrition and physical activity.
• Beneficiaries must be at least 18 years vintage and have a Body Mass Index (BMI) of 35 or greater.
• Alternatively, beneficiaries with a BMI of 30 or greater may qualify if they have been diagnosed with one or more of the following conditions: heart failure with preserved ejection fraction, uncontrolled hypertension (systolic blood pressure above 140 mm Hg or diastolic blood pressure above 90 mm Hg despite concurrent treatment with two antihypertensive medications), or chronic kidney disease stage 3a or above.
• Beneficiaries with a BMI of 27 or greater may qualify if they have been diagnosed with pre-diabetes, previous myocardial infarction, previous stroke, or symptomatic peripheral artery disease.

How the Program Works

The $50 monthly payment will not be applied towards the beneficiary’s annual deductible. This program, known as the Medicare GLP-1 Bridge, will operate outside of the traditional Medicare Part D benefit structure. This means that Part D sponsors are not directly involved in the program and will not bear any financial risk for the medications provided through the bridge.

The Centers for Medicare & Medicaid Services (CMS) will utilize a single central processor to manage prior authorization, claims adjudication, and payment to pharmacies CMS.

The BALANCE Model and Future Coverage

The Medicare GLP-1 Bridge is designed as a temporary measure leading up to the implementation of the BALANCE (Better Approaches to Lifestyle and Nutrition for Comprehensive Health) Model, scheduled to begin in January 2027. Through BALANCE, CMS will negotiate drug pricing and coverage of GLP-1 medications on behalf of state Medicaid agencies and Medicare Part D plan sponsors. Part D sponsors who wish to participate in the BALANCE Model must apply and be approved by CMS, with additional information regarding participation requirements expected in March 2026 CMS.

What are GLP-1 Medications?

GLP-1 (glucagon-like peptide-1) receptor agonists are a class of drugs initially developed to treat type 2 diabetes. They work by mimicking the effects of the GLP-1 hormone, which helps regulate blood sugar levels, promotes feelings of fullness, and can lead to weight loss. Medications in this class include Ozempic, Rybelsus, and Wegovy, with Wegovy and Zepbound being selected for initial price applicability in 2027 under the Medicare Drug Price Negotiation Program CMS.

Will Medicare Cover Weight-Loss Medications in the Future?

Currently, Medicare generally does not cover weight-loss medications GoodRx. Yet, the introduction of the BALANCE Model and the Medicare GLP-1 Bridge signal a shift towards greater coverage of these medications for eligible beneficiaries. The long-term coverage and cost of GLP-1 medications will depend on the outcomes of the BALANCE Model and future negotiations between CMS and drug manufacturers Wellcare.